Congressmen Call On GAO To Update Behind-The-Counter Class Investigation

The Government Accountability Office should update its 1995 study of behind-the-counter drug regulatory schemes in o0ther countries to better educate FDA as it considers a third class of drugs in the U.S., members of the House Energy and Commerce Committee say in a Jan. 16 letter to the GAO